Alizé Pharma signs research collaboration and license option agreement with Lilly
Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of Type II diabetes
27-Jan-2010 -
Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, announced that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company regarding Alizé Pharma's AZP-01 program, a program focused on ...
diabetes
Eli Lilly
ghrelin
+6